In studies of ovarian and breast cancers, increased TLE3 expression was related to a higher response rate to taxane-based chemotherapy, but TLE3 expression showed no predictive value in treating breast cancer at an early stage (Samimi et al., 2012; Ring et al., 2018). The gene discussed is TLE3; the disease is breast cancer.